Literature DB >> 17012257

Detection of novel intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging.

Jochen Klucken1, Tiago F Outeiro, Paul Nguyen, Pamela J McLean, Bradley T Hyman.   

Abstract

Oligomerization and aggregation of alpha-synuclein molecules are believed to play a major role in neuronal dysfunction and loss in Parkinson's disease (PD) and dementia with Lewy bodies. However, alpha-synuclein oligomerization and aggregation have been detected only indirectly in cells using detergent extraction methods. Here, we show for the first time intracellular alpha-synuclein oligomerization using fluorescence lifetime imaging (FLIM). Two forms of alpha-synuclein homomeric interactions were detected: an antiparallel amino terminus-carboxyl terminus interaction between alpha-synuclein molecules, and a close amino terminus-carboxy terminus interaction within single alpha-synuclein molecules. Coexpression of the chaperone protein Hsp70, which can block alpha-synuclein toxicity in several systems, causes alpha-synuclein to adopt a different, open conformation, but Hsp70 does not alter alpha-synuclein-alpha-synuclein interactions. Thus, the neuroprotective effect of Hsp70 can be explained by its chaperone activity on alpha-synuclein molecules, rather than alteration of alpha-synuclein-alpha-synuclein interactions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17012257     DOI: 10.1096/fj.05-5422com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  38 in total

1.  Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway.

Authors:  Jochen Klucken; Anne-Maria Poehler; Darius Ebrahimi-Fakhari; Jacqueline Schneider; Silke Nuber; Edward Rockenstein; Ursula Schlötzer-Schrehardt; Bradley T Hyman; Pamela J McLean; Eliezer Masliah; Juergen Winkler
Journal:  Autophagy       Date:  2012-05-01       Impact factor: 16.016

Review 2.  Drug targets from genetics: α-synuclein.

Authors:  Karin M Danzer; Pamela J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

Review 3.  Molecular chaperones in Parkinson's disease--present and future.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

4.  Chaperone proteostasis in Parkinson's disease: stabilization of the Hsp70/alpha-synuclein complex by Hip.

Authors:  Cintia Roodveldt; Carlos W Bertoncini; August Andersson; Annemieke T van der Goot; Shang-Te Hsu; Rafael Fernández-Montesinos; Jannie de Jong; Tjakko J van Ham; Ellen A Nollen; David Pozo; John Christodoulou; Christopher M Dobson
Journal:  EMBO J       Date:  2009-10-29       Impact factor: 11.598

5.  In vivo cross-linking reveals principally oligomeric forms of α-synuclein and β-synuclein in neurons and non-neural cells.

Authors:  Ulf Dettmer; Andrew J Newman; Eric S Luth; Tim Bartels; Dennis Selkoe
Journal:  J Biol Chem       Date:  2013-01-14       Impact factor: 5.157

Review 6.  Molecular chaperones and co-chaperones in Parkinson disease.

Authors:  Hemi Dimant; Darius Ebrahimi-Fakhari; Pamela J McLean
Journal:  Neuroscientist       Date:  2012-07-24       Impact factor: 7.519

7.  Assessing the subcellular dynamics of alpha-synuclein using photoactivation microscopy.

Authors:  Susana Gonçalves; Tiago Fleming Outeiro
Journal:  Mol Neurobiol       Date:  2013-02-08       Impact factor: 5.590

8.  DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70.

Authors:  Sara Batelli; Diego Albani; Raffaela Rametta; Letizia Polito; Francesca Prato; Marzia Pesaresi; Alessandro Negro; Gianluigi Forloni
Journal:  PLoS One       Date:  2008-04-02       Impact factor: 3.240

9.  Dopamine-induced conformational changes in alpha-synuclein.

Authors:  Tiago F Outeiro; Jochen Klucken; Kathryn Bercury; Julie Tetzlaff; Preeti Putcha; Luis M A Oliveira; Alexandre Quintas; Pamela J McLean; Bradley T Hyman
Journal:  PLoS One       Date:  2009-09-04       Impact factor: 3.240

10.  Drug Targeting of alpha-Synuclein Oligomerization in Synucleinopathies.

Authors:  Tiago Fleming Outeiro; Aleksey Kazantsev
Journal:  Perspect Medicin Chem       Date:  2008-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.